206111-40-2 Usage
Piperidine derivative
The compound is derived from a piperidine ring, which is a six-membered heterocyclic ring containing one nitrogen atom.
Two ester groups
The compound contains two ester groups, which are functional groups formed by the combination of an alcohol and a carboxylic acid.
tert-Butyl and ethyl groups
The compound has one tert-butyl group and one ethyl group attached to the piperidine ring, contributing to its structure and properties.
Common use as intermediate
1-tert-butyl 4-ethyl 3-oxopiperidine-1,4-dicarboxylate is often used as an intermediate in the synthesis of pharmaceuticals and organic compounds.
Potential applications
The compound has potential applications in the fields of organic chemistry, medicinal chemistry, and drug discovery.
Biological activity
The compound has shown biological activity, which means it may interact with biological systems and have potential therapeutic effects.
Value in pharmaceutical industry
Due to its biological activity and potential applications, the compound is being studied for its possible use in the pharmaceutical industry.
Research tool
The compound's structure and properties make it a valuable tool for researchers and chemists in various fields, aiding in the development of new compounds and understanding of chemical reactions.
Check Digit Verification of cas no
The CAS Registry Mumber 206111-40-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,6,1,1 and 1 respectively; the second part has 2 digits, 4 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 206111-40:
(8*2)+(7*0)+(6*6)+(5*1)+(4*1)+(3*1)+(2*4)+(1*0)=72
72 % 10 = 2
So 206111-40-2 is a valid CAS Registry Number.
206111-40-2Relevant articles and documents
Discovery of a brain-penetrant S1P3-sparing direct agonist of the S1P1 and S1P5 receptors efficacious at low oral dose
Demont, Emmanuel H.,Arpino, Sandra,Bit, Rino A.,Campbell, Colin A.,Deeks, Nigel,Desai, Sapna,Dowell, Simon J.,Gaskin, Pam,Gray, James R. J.,Harrison, Lee A.,Haynes, Andrea,Heightman, Tom D.,Holmes, Duncan S.,Humphreys, Philip G.,Kumar, Umesh,Morse, Mary A.,Osborne, Greg J.,Panchal, Terry,Philpott, Karen L.,Taylor, Simon,Watson, Robert,Willis, Robert,Witherington, Jason
supporting information; experimental part, p. 6724 - 6733 (2011/12/04)
2-Amino-2-(4-octylphenethyl)propane-1,3-diol 1 (fingolimod, FTY720) has been recently marketed in the United States for the treatment of patients with remitting relapsing multiple sclerosis (RRMS). Its efficacy has been primarily linked to the agonism on
